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The interest in adipogenesis stems from the high rate of obesity in the world and 
the motivation to better understand the process of cell fate in relation to human diseases. 
Mutations in MED12 lead to developmental disorders and certain malignancies. To date, 
specific roles of Mediator and MED12 in cell state regulation are unclear, nevertheless, 
they are critical for understanding stem cell regulation and enhancement of their clinical 
applications. This study investigates the role of MED12 in relation to the Mediator complex 
kinase domain to better understand transcriptional control of adipogenesis in hASCs. In 
this study, MED12 expression was diminished with MED12 specific siRNA and 
adipogenesis was induced/assessed at different time points (day 3,7 and 14) using phase 
imaging to detect lipid droplets with Oil red-O staining being used to further validate 
differentiation and visualize the cells. To validate and confirm the effects of the MED12 
knockdown, qRT-PCR and western blot analysis was carried out. To determine the role of 
MED12 as it functions in the Mediator complex and its role in maintaining the structural 
integrity of the kinase module, Coimmunoprecipitation assays were carried out. Results 
from this study show that in the absence of MED12, there is a significant decrease in the 
number of lipid vesicles compared to the negative control as observed via oil red-O staining 
and a decrease in the expression of adipogenic transcription factors such as PPARγ and 
C/EBPα via qRT-PCR and western blot analysis. Results also indicated that MED12 
interacts with the adipogenic transcription factors to direct proper gene expression and 




indicates a role for MED12 and the Mediator complex in directing the process of 
transcription during adipogenesis. Taken together, these data suggest a significant role for 
MED12 in regulating adipogenesis and will initiate new research into understanding the 
regulatory mechanisms of adipogenesis and offer insight into novel treatments for obesity 
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1.1 Stem Cells 
        Stem cells are undifferentiated cells that have self-renewing capabilities and 
the potential to differentiate into multiple lineages and cell types. They are found in 
multicellular organisms and are part of a repair system that aids in regeneration following 
tissue damage1. Stem cells renew themselves through cell division and can be induced to 
form organ specific cells. Also, stem cells are employed for the treatment and prevention 
of diseases, including the treatment of cancer1.  
Stem cells are categorized into two groups: embryonic stem cells (ESCs) and adult 
stem cells. ESCs are derived from the inner cell mass of a developing blastocyst and are  
pluripotent, giving rise to cells from all three germ layers: ectoderm, mesoderm and 
endoderm1,2. Embryonic stem cells have greatly contributed to our understanding of 
developmental biology and advancements in medicine. These cells were the primary focus 
of stem cell research in the 1990s and early 2000s, but due to the ethical and political 
concerns about the source of these cells, efforts have been made to identify and characterize 
additional sources of stem cells that are more easily obtained and even more clinically 
relevant3.  
Adult stem cells (ASCs) are multipotent cells characterized and named after their 
tissue of origin: umbilical cord blood, adipose tissue, blood, placenta, etc.  Examples of 




adult stem cells include hematopoietic stem cells, which are isolated from the bone marrow 
and give rise to blood cells and mesenchymal stem cells found in bone marrow, adipose 
tissue, and umbilical cord blood or tissue, that gives rise to connective tissues and bones. 
Adipose stem cells are under recent intense investigation as they have the potential to 





       Adipose stem cells are the focus of current research because adipose tissue is 
relatively abundant in the human body and can be easily collected in large quantities, with 
fewer donor site injuries3,4. Subcutaneous adipose tissue is the most clinically applicable 
source of ASCs and is retrieved from the abdomen, arm, or thigh of the human body4. Due 
to its mesodermal origin, ASCs differentiate into adipogenic, osteogenic, chondrogenic and 
neurogenic lineages through a complex cascade of transcriptional and non-transcriptional 
pathways. Also, adipose stem cells have the potential to differentiate into various cells of 
the endodermal and ectodermal lineages including neuron-like cells, endothelial cells, 
pancreatic cells, and hematopoietic cells5. 
Figure 1-1:  Human mesenchymal stem cells are derived from multiple 
adult tissues in the body and undergo differentiation into various lineages. 
(Figure adapted from Katsuda et al 2013 and generated by Rachel Eddy in 
the Newman lab). 




1.2 Clinical applications of adipose stem cells 
Presently there is great clinical potential for adult stem cells derived from adipose 
tissue, blood, and bone marrow, which makes these stem cells potential targets for clinical 
research and regenerative medicine. Adult stem cells have immunomodulatory properties 
that have influenced their use as an effective option to treat autoimmune and inflammatory 
conditions, like multiple sclerosis4. Adult stem cells secrete numerous growth factors and 
cytokines which are necessary for wound healing as they contribute to improved 
vascularization in wounds, increased macrophage recruitment, and enhanced tissue 
granulation in wound healing6. A study by Rigotti et al in 2007 showed that adult stem 
cells were useful in the treatment of wounds complicated by ischemia in patients living 
with diabetes7. This study led to further findings that adult stem cells may be effective in 
the treatment of several other conditions such as atrophy, fibrosis, retractions, and ulcers 
induced by radiation therapy7.  
Adipose stem cells in regenerative medicine have shown great clinical potential in 
bone regeneration and are currently yielding exciting and promising results. For example, 
in 2004, Landeckal et al described the first clinical use of adipose stem cells in a 7-year old 
girl reported to have calvarial defects after severe head injury with multi-fragment calvarial 
fractures8, 9. Stromal vascular fraction (SVF) obtained from adipose tissue was placed at 
various locations of the fracture and computed tomography scans showed the formation of 
new bone three months after the reconstruction9. From this research it was observed that 
adipose stem cells have greater advantages when compared to bone marrow derived 
mesenchymal stem cells especially with regards to cell yield for pediatric patients9. 
Adipose stem cells are being investigated for their therapeutic effects in particular 




chondrocytes, cardiac wall regeneration, functional repair after myocardial infarction, and 
functional improvement after stroke10. Studies have shown that adipose stem cells may be 
a better option for clinical trials due to its high yield in the body and the fact that they 
require minimal manipulation before delivery11,12.  
1.3 Adipogenesis 
     Adipose tissue is a multifaceted organ that performs several important 
physiological functions such as lipid metabolism, whole-body insulin sensitivity and 
systemic energy homeostatis13–15. Adipose tissue consists of several cell types including 
endothelial cells, fibroblasts, macrophages, pericytes and other immune cells14. The major 
function of adipocytes is to store energy in the form of triglycerides to be used during 
periods of calorie insufficiency. Adipogenesis follows commitment and is when 
undifferentiated precursor cells restrict their fate to the adipogenic lineage, accumulate 
nutrients, and differentiate into filled mature fat cells13,15–20 (Figure 1-2).  
Several families of transcription factors along with external cues from the environment 
drive adipogenesis. PPARγ, C/EBPα C/EBPβ, EGR1, EGR2 and SREBP1c are specific 
transcription factors that have been shown to induce early adipogenesis, with PPARγ  being 
the most critical transcription factor required for adipocyte cell development, early 
adipogenesis and lineage commitment21.  
 
 








The process of adipogenesis in vitro is a highly ordered and well-characterized 
sequence of events. It starts with a growth arrest of proliferating pre-adipocytes in cultured 
cell lines induced by the addition of a pro-differentiation hormone regimen and by an 
additional round of clonal expansion (cell division)14. During adipocyte cell differentiation, 
PPARγ, the master regulator of adipogenesis, increases in expression and activity in 
fibroblasts or myocytes promoted to undergo adipogenesis. Previous studies have 
suggested that PPARγ is involved in adipogenesis because it is observed at higher levels 
in adipocytes of morbidly obese individuals as compared to individuals with a normal body 
weight21. The systematic coordination of signaling pathways and transcription factors 
requires critical regulation to properly monitor changes in gene expression. This suggests 
that the transcription factors must be activated or repressed in a specified sequence while 
inhibiting other lineage fates of adult stem cells that are also set up to undergo 
differentiation into myoblasts, chondrocytes, or osteocytes17. 
1.4 Transcription and Control of Gene Expression 
Transcription is the first step in gene expression. During transcription, information 
from a gene is used to initiate construction of a functional product such as a protein or non-
Figure 1-2:   The differentiation of hASCs to lipid filled adipocytes. This 
is a 21-day process in the lab that yields visible lipid vesicles that can be 
stained using Oil Red O.  Illustration credit: Jessica Trinh, VISTA Center.  




coding regulatory RNA. Transcription factors are proteins that bind to specific sequences 
of the DNA to direct transcription22. Transcription factors rely on coactivators to 
communicate with the general transcription machinery, and they ensure that biological 
inputs received from signaling cascades are translated into specific gene expression 
programs. It is noteworthy to state that transcription factors control the gene expression 
programs that establish and maintain the state of the cells23. Three classes of transcription 
factors that influence adipocyte cell development have been identified. They include the 
PPAR family, C/EBPs and the ADD1/SREBP family.  
PPARγ, the master regulator of adipogenesis, is the most specific of the PPAR 
family of transcription factors in adipogenesis and is expressed at very high levels in 
adipose tissues and adipocyte cell lines24,25. PPARγ is a subgroup of the nuclear hormone 
receptor and is implicated in the transcriptional activation of adipocyte differentiation. 
PPARγ can induce adipocyte differentiation of preadipocytes, myoblasts and multipotent 
stem cells and is necessary to promote adipocyte cell differentiation. PPARγ must 
heterodimerize with another nuclear hormone receptor to bind DNA and be 
transcriptionally active. Each member of the PPAR family serves different functions in 
vivo26. They exhibit unique tissue distribution and have different affinities for different 
response elements. PPARγ activates the promoters of many other fat cell specific genes 
and can be activated by synthetic compounds such as thiazolidinediones (TZDs) which are 
used as anti-diabetic agents24,25.  
The C/EBP family consists of six isoforms, all of which belong to a basic leucine 
zipper class of transcription factors. C/EBPs undergo transcriptional regulation at many 
levels and are measured by mRNA levels present in the cells. cAMP, an inducer of 




adipogenesis, enhances the expression of C/EBPα and C/EBPβ.  Both in vitro and in vivo 
experiments have established that C/EBPs (α, β, and δ) promote adipocyte differentiation. 
Results from in vivo studies carried out in mice observed that C/EBPβ and C/EBPδ 
deficient mice showed a phenotype having substantially low lipid accumulation27. 
The adipocyte determination and differentiation factor 1 (ADD1/SREBP1c) family 
belong to the basic helix-loop-helix family of transcription factors. SREBP1c plays a role 
in tissue specific gene regulation of muscles within the same mesodermal origin with fat 
cells28–30. Previous studies have shown that SREBP1 family induces preadipocyte cells to 
differentiate into mature fat cells and the overexpression resulted in high levels of 
adipocyte marker expression and lipid deposit accumulation within the cells29. Previous 
studies have shown a relationship between SREBP1 and PPARγ which leads to an increase 
in transcriptional activity when they work together as compared to SREBP1 alone. This 
may suggest that ADD1/SREBP may be responsible for generating some factors that 
enhance the activity of PPARγ25,27,29. 
 
1.5 The Mediator Complex 
The human Mediator complex is a large 1 million Dalton macromolecular complex 
that is conserved in all eukaryotes from yeast to humans. The Mediator complex consists 
of 25-31 subunits, depending on organism, and is arranged in four modules: the head, the 
middle, the tail and the kinase module which consists of MED12, MED13, CDK8 and 
Cyclin C31 (Figure 1-3). American chemist Roger Kornberg first discovered the Mediator 
complex in 1990 and in 2006 won a Nobel Prize in Chemistry for his research on the 
molecular basis of eukaryotic transcription. Kornberg’s research was centered on 




transcription and understanding how genetic materials are transferred to different parts of 
the body, a process that is vital to an organism’s existence32. The mammalian Mediator 
complex exists in two forms and comprises up to 30 proteins. The core Mediator complex 
contains 26 subunits and is required as a strong coactivator of transcription while the other 
form, referred to as MED12-Mediator, consists of the kinase module and the 26 core 
subunits. The MED12-Mediator complex is capable of regulating transcription both 
positively and negatively, depending on context. Alterations of specific subunits of the 
Mediator complex is usually associated with several developmental disorders and human 
diseases such as Lujan syndrome, Opitz-Kaveggia syndrome, schizophrenia, cancer, and 






Figure 1-3: Mediator is a 30-subunit complex comprised of four modules that 
links the various interactions between enhancer-bound, cell-type specific 
transcription factors and transcriptional machinery at gene promoters. 




The observable function of Mediator is to link interactions between the enhancer-
bound specific transcription factors that regulate the cell fate to the promoter region of the 
target genes. Mediator can physically interact with a collection of transcriptional regulatory 
proteins, including DNA-binding transcription factors, RNA polymerase II, general 
initiation factors, and transcription elongation factors. Also, Mediator has been used as a 
factor in the identification of super enhancers. Super enhancers are referred to as elements 
of the genome where a significant number of cell type specific transcription factors come 
together to direct transcription(Figure 1-4)36–38. Because of these interactions, mutations or 
alterations of the Mediator complex can contribute to many types of cancer, as well as 
neurological, developmental, and metabolic disorders36. 
The head and middle module play an essential role in stabilizing the interaction of 
transcription factors and RNAP II during pre-initiation complex (PIC) assembly on a cell 
type specific promoter35, while the tail module interacts with transcription factors which 
are bound to peripheral gene regulatory elements35. Also, the tail module, together with the 
kinase module works to regulate the head and middle subunits. Deleting the kinase domain 
of the Mediator complex leads to stressed genes. CDK8 can phosphorylate MED3 (tail 
domain) and this leads to a decrease in transcriptional activation and subsequent decrease 
in MED3 subunit expression36. Also, CDK8 can phosphorylate transcriptional activators 
that are bound to the enhancer. MED13 acts as the connector between the kinase domain 
and the rest of Mediator and is the target for most tumor suppressors and auxin-regulated 
co-repressors that act through the upstream regulatory region36. 









         During cell culture studies, research has shown that the Mediator complex can be 
isolated from cell extracts with or without the kinase module and studies have shown that 
the kinase module can block interactions between Mediator and RNA polymerase II 
enzyme36. In vitro transcription studies carried out on the Mediator complex show that the 
absence of the kinase module renders the complex transcriptionally active while the 
presence of the kinase domain renders the complex transcriptionally inactive. However, 
little information exists to describe how these forms of Mediator are involved in 
transcription in vivo. The Mediator complex plays an active role in transcription initiation 
at core promoters that is different from its role at the enhancer region. This distinct property 
Figure 1-4: Mediator is a 30- subunit complex, comprised of four modules that 
bridges long-range interactions between enhancer-bound, cell-type specific 
transcription factors and transcriptional machinery at gene promoters. (Figure 
adapted from Straub J, Venigalla S, Newman JJ. Mediator’s Kinase Module: A 
Modular Regulator of Cell Fate. Stem Cells Dev. 2020;29(24):1535-1551. 
doi:10.1089/scd.2020.0164). 




of the Mediator complex at the enhancer and promoter region raises the possibilities that 
there may be a change in a single Mediator complex during transcriptional activation39–41. 
The kinase module of the Mediator complex, which is made up of MED12, MED13, CDK8 
and CCNC is associated with the rest of the Mediator through MED13 and has been shown 
to be the only portion of the complex that demonstrates enzymatic activities. Knockdown 
studies on any of the subunits have been shown to exhibit cell-type specific effects on 
transcription and in regulation of cell fate and lineage commitment and this suggests a 
unique role of the module and this makes it very vital to study. 
 
1.6 MED12 
MED12 has been shown to play a major role in stem cell regulation through 
interactions with CDK8 and Cyclin C enzymatic activity. In human cells, the kinase 
domain has been shown to be involved in the phosphorylation of certain transcription 
factors such as the SREBP family and it is involved in lipid and carbohydrate metabolism 
in yeast42. MED12 interactions have been implicated in ESC differentiation and 
embryogenesis, as well as adult stem cell maintenance and potency43,44. MED12 acts as a 
molecular switch that shuts down activated transcription upon binding to Mediator by 
blocking re-initiation by RNAP II45. To date, specific roles of Mediator and MED12 in cell 
state regulation are unclear, nevertheless, they are critical for understanding stem cell 
regulation and enhancement of their clinical applications45. 
 





MED13 plays a vital role in the kinase module and connects the kinase domain to 
the rest of the Mediator complex and has been known to play a role in developmental 
processes in the cell. For example, MED13 regulates developmental gene expression 
profiles in Drosophilia, Dano rerio (Zebrafish) and C. elegans46,47. Previous studies have 
shown in mice that when MED13 is overexpressed, it forms a direct connection to CDK8 
and the general Mediator complex. Also, MED13 plays an essential role in energy 
homeostasis of the heart by regulating the expression of thyroid genes which play a role in 
regulating energy homeostasis48. 
1.8 CDK8 and CCNC 
Cyclin-dependent kinases (CDKs) are a group of serine/threonine protein kinases 
that are required for early embryogenesis and they serve as key regulators of both cell cycle 
and transcription. CDK8 kinase activity has been linked to its ability to bind both CCNC 
and MED12 by regulating the transcription factors involved in phosphorylation and 
impacting the key transcriptional outputs that affect cellular and developmental 
homeostasis49–51. Cyclin-dependent kinases (CDKs) are a group of serine/threonine protein 
kinases that are required for early embryogenesis and they serve as key regulators of both 
cell cycle and transcription. CDK8 kinase activity has been linked to its ability to bind both 
CCNC and MED12 by regulating the transcription factors involved in phosphorylation and 
impacting the key transcriptional outputs that affect cellular and developmental 
homeostasis49–51.  
  




1.9 Research needs and Motivation 
Previous studies have linked the kinase domain, specifically MED12 and MED13 
to the regulation of gene expression during development. Both MED12 and MED13 play 
a vital role in eye and wing development in Drosophilia where the absence or loss of 
MED12 resulted in physiological differences of wing structure. In zebrafish, MED12 has 
been linked as a co-factor in neural crest and endoderm development 55. Previous studies 
have also identified MED12 as being essential for CDK8 and CCNC enzymatic activity. 
MED12 interacts with CDK8 through a physical association with Cyclin C (CCNC), thus 
making it vital to the function of the kinase domain43. Although the mechanism via which 
MED12 performs this function is unknown, MED12 dependent CDK activation is essential 
for nuclear transduction of the signals which are propagated by the different signaling 
pathways in which MED12 is genetically and biochemically linked56. The loss of MED12 
may lead to mutations and dysfunction that may result in mis-regulation of gene 
expression. MED12 has been extensively studied in embryonic stem cells and 
hematopoietic stem cells but to date, there is no study on the role of MED12 in human 
adipose stem cells and its potential in driving adipogenesis and cell fate.  
There is great clinical interest and therapeutic potential that comes from 
understanding human adult stem cells. Adult stem cells have the potential to regenerate 
whole organs from a few cells and have the potential to be used in a variety of tissue 
engineering and regenerative medicine applications. Human adipose stem cells (hASCs), 
the adult stem cells used in the studies described here, are multipotent and can differentiate 
into cell types of multiple lineages.  




In the human body, negative modifications or mutations within the Mediator 
complex may give rise to developmental diseases such as Lujan syndrome, Schizophrenia 
and Optiz-Kaveggia syndrome. Mediator’s mechanism of action lies in the fact that it 
functions to bridge the interactions between the cell-type specific transcription factors at 
the enhancer region to the promoter region. A mutation in this role of the complex will lead 
to a physical change in genomic architecture and communication within the cells may be 
brought to a halt, resulting in disruption to cell fate43. The role of MED12 in normal cell 
state and differentiation remain unclear, however, we are interested in studying 
adipogenesis and transcriptional control of adipogenesis in a human model to provide 
critical insights into causes of dysregulation and aberrant gene expression.  
Understanding the molecular mechanism through which stem cell state is regulated 
and adipogenesis is controlled will allow for the enhanced clinical application of these cells 
in the future. Through the investigation of the kinase module of the Mediator complex we 
can gain greater insight into how cell-type specific gene expression profiles are regulated, 
the role of MED12 as a co-factor in interacting with adipogenic-specific transcription 







2.1 The effects of MED12 knockdown on adipogenesis in hASCs 
2.1.1 Introduction  
MED12, a critical subunit found in the kinase module of the Mediator complex, has 
been extensively studied in embryonic stem cells and hematopoietic stem cells. However, 
to date, there is no study on the role of MED12 in human adipose stem cells and its potential 
in driving adipogenesis and cell fate. There is great clinical interest and therapeutic 
potential that comes from understanding human adult stem cells. Adult stem cells, of which 
adipose stem cells are a class, have the potential to regenerate whole organs from a few 
cells and have the potential to be used in a variety of tissue engineering and regenerative 
medicine applications. In addition, adult stem cells have immunomodulatory properties and 
can be used as a therapeutic option in the treatment of certain autoimmune and 
inflammatory conditions. Mediator’s mechanism of action lies in the fact that it functions 
to bridge the interactions between cell-type specific transcription factors located at the 
enhancer region to the transcriptional machinery at the promoter. A mutation in a subunit 
of the complex may lead to a physical change in gene expression and communication 
within the cells may be brought to a halt, ultimately causing a disruption in cell fate.  
The precise role of the Mediator complex and each of its subunits in development 
and disease remains vague despite numerous studies attempting to determine how 
individual subunits function during lineage commitment and development. The kinase 




domain, made up of CDK8, CCNC, MED12, and MED13, is associated with the Mediator 
complex through MED13 and it is the only portion of the complex that has been shown to 
demonstrate enzymatic activities.  Previous studies have shown that a mutation in any 
subunit of the kinase module does not have an impact on gene expression but influences 
cell-type specific transcription factors which suggests that the Mediator complex may be 
responsible for directing cell fate and commitment.  The kinase domain, just like the 
Mediator complex, occupies enhancer elements and has been shown to phosphorylate 
specific transcription factors such as PPARγ and C/EBPα that occupy these same genomic 
regions.  
We initially sought to determine the role of MED12 in adipogenesis. This was 
achieved by assessing the phenotypic changes in the cells during adipocyte differentiation 
following the siRNA-mediated knockdown of MED12. To address this objective, we used 
hASCs and monitored the effects that the knockdown of MED12 has on gene expression 
levels of the cells following induction of adipogenesis. Results of this study indicate a 
regulatory role for MED12 in directing adipogenesis and lead towards an additional 
understanding of how MED12 controls cell-type specific gene expression profiles. For the 
next study, we ran Coimmunoprecipitation assays (CoIPs) to determine the interaction of 
the subunits within the kinase module.  The aim of this objective is to determine the role 
of MED12 as it functions in the Mediator complex and its role in maintaining the structural 
integrity of the kinase module. Given the importance of C/EBPα, and PPAR during 
adipogenesis, we predicted that MED12 interacts with the transcription factors and kinase 
module to direct gene expression.  




2.2 MATERIALS AND METHODS 
2.2.1 hASCs Cell Culture 
Culture Media: Human adipose-derived stem cells were purchased from Obatala 
LLC and were received frozen in cryotubes at Passage 1 and stored in liquid nitrogen.  The 
cells were maintained in complete culture medium (CCM) containing 203.75ml MEM 
Alpha (1X) (gibco;12561-049), 2.5ml of 1% L-glutamine (L-Glut) 200mM (100X) (gibco; 
25030-081), 2.5ml of 1% penicillin streptomycin (gibco; 15140-122), and 41.25ml of 
16.5% fetal bovine serum (FBS) (ATLANTA Biologicals; S11150). All components were 
combined and filtered through a 0.22µm 250ml filter system (Corning; 430756). CCM 
solution was stored at 4oC. 
2.2.2 Cell Thawing 
Cells were removed from the liquid nitrogen and thawed quickly using a water bath 
at 37oC. The cells were transferred to a 15ml conical tube containing 4ml of warm CCM 
and the tube was centrifuged at room temperature at 1500RPM for 10 minutes. At the end 
of the centrifugation, the supernatant was aspirated using a sterile Pasteur pipette and the 
cell pellet was resuspended in 10ml of CCM and incubated at 37°C at 5% CO2 . CCM media 
was changed every 2 days until cells reached 70-80% confluency, at which point they were 
passaged for continued expansion and for use in specific assays, as described below.  
 
2.2.3 Cell Passaging  
When cells reached appropriate confluency, they were rinsed using phosphate 
buffered saline (PBS) (gibco; 10010-023). The cells were detached from the tissue culture 
plates using 0.25% Trypsin-EDTA (1X) (gibco; 25200-056). Cells were then transferred 




to a conical tube containing CCM and centrifuged at room temperature at 1500RPM for 10 
minutes. At the expiration of the centrifugation, the supernatant was aspirated, and cells 
were resuspended in 1ml of CCM media. Cells were then counted by gently mixing 12µl 
of the cell suspension and 12µl of Trypan Blue 0.4% (Lonza; 17-942E) in a 1.5ml 
Eppendorf tube. Half of the solution was added to each side of a reusable hemocytometer 
(Life Technologies, A25750) and counted with a Countess II FL automated cell counter 
(Thermo Fisher AMQAX1000). Based on the live cell count, the desired number of cells 
was plated for the different experiments to be carried out (Table 2-1). To calculate the 
volume of cell suspension needed for the experiments, the desired cell number to be plated 
was divided per milliliter of CCM used. For example, to plate 100,000 cells from a cell 
pallet suspended in 1ml of media with a live cell count of 1.5*106, 
(100,000/1.5*106)/1000µLs, 66.67µLs of cell suspension will be seeded.  
 
 




Type of experiment 
15cm  150,000 cells 15 Passage, ChIP assay 
10cm 100,000 cells 10 Passage, Protein, differentiation, and 
transfection 
6cm 45,000 cells 3 RNA, differentiation, and transfection 
6-well 20,000 cells/well 2 Differentiation, transfection, and some 
staining techniques such as Oil-Red O 
96-well 400 cells/well 0.2 Cell viability 
 
Table 2-1: Cell seeding density for different tissue culture plate types 




2.2.4 Transfection  
When cells reached 40% confluency, hASCs were transfected with 10µM stock 
solutions of MED12 silencer select siRNA (Ambion; 4392420) or silencer select negative 
control #1 siRNA (Ambion; 4390843), using lipofectamine RNAiMAX reagent 
(Invitrogen; 56531) and Opti-MEM I (1X) (gibco; 31985-062) following the 
manufacturer’s protocol. 24 hours after transfection media was replaced with adipogenic 
differentiation media. 
2.2.5 Adipogenic Differentiation  
Adipogenesis was initiated in cells 24 hours after transfection by replacing CCM 
with adipogenic differentiation media (AdipoQualTM Obatala, LaADM-500). Media was 
changed every 72 hours until the different time points for the experiments were achieved.  
2.2.6 Oil Red-O Staining 
At the conclusion of each time point, a set of cells was fixed in formalin (Azer 
Scientific, NBF-4-G) for 15 minutes at room temperature. The formalin was aspirated and 
washed with PBS (gibco; 10010-023). The cells were stained with Oil Red-O 
(Amresco,1320-06-5) and incubated at room temperature for 20 minutes and rinsed with 
PBS three times. Phase-contrast imaging was used to detect lipid droplets with Oil Red-O 
staining being used to further validate differentiation and visualize the cells. 
To quantify cell differentiation, Oil Red-O was extracted from fixed samples, and 
the absorbance was quantified with a plate reader. To extract the stain, 100% Isopropanol 
(IBI 15735) was added to each well and allowed to incubate for 1 hour. 100µL of each 
sample were transferred to a 96-well plate. Proteins were extracted from the remaining 
cells using RIPA buffer (Abcam ab156034). The absorbance was read with a plate reader 




at optical density 540nm, and the protein was quantified using a Bradford assay. The 
absorbance readout of the stain was normalized to the concentration of protein extracted 
from the wells. 
2.2.7 RNA Extraction 
Cells were seeded on 6 cm plates for RNA extraction. RNA was collected from the 
cells by rinsing with sterile PBS and extracted using TRIZOL reagent (Life Technologies 
15596018) according to the manufacturer’s protocol for RNA extraction. RNA 
concentrations were determined using the BioTek Cytation Take3 plate reader. 1µg of 
RNA was used to generate cDNA using qScriptTM cDNA super mix (Quanta Biosciences, 
95048-100) following the manufacturer’s protocol.  
2.2.8 Quantitative Reverse Transcriptase PCR 
Complimentary DNA (cDNA) was prepared with the use of the Quanta Q-script 
mix manufacturer’s protocol (Quanta Biosciences, 95048-100), along with nuclease free 
water (Quality Biological 351029721). qRT-PCR was performed using PowerUPTM SYBR 
Green PCR master mix (Life technologies 1708033) and was run using the manufacturer’s 
protocol on the Applied Biosystems StepOne PlusTM with annealing temperatures of 50oC 
and extension at 60oC for 35 cycles. Gene expression levels were normalized to GAPDH 
using CT values. Relative remaining transcript and fold change were calculated using the 
2-ΔΔCT method. The results were reported as an average of three biological replicates and 
the error bars was representative of the standard error of the mean. All primers used for the 
PCR analysis are listed in table 2-2 below. 
 
 





Gene Forward sequence (5ʹ-3ʹ) Reverse sequence (5ʹ-3ʹ) Product 
size 
(bp) 
Gapdh CCCCACTTGATTTTGGAGGGA AGGGCTGCTTTTAACTCTGGT 206 
med12 CGAAAAGGGACAGCAGAAAC CCCATCCTCCCCACCTAAGA 87 
med13 TGTCCTGCTCCTTCACCTTTT GGCATAAGATAACTTGAAATGGGCT 150 
Ccnc GCTGATTTGATCGAGGAGCG ATCCATTGCAAATAGTGGGAGC 148 
cdk8 GCCAAGAGGAAAGATGGGAAGG GCCGACATAGAGATCCCAGTT 77 
pparγ GCTGTTATGGGTGAAACTCTG ATAAGGTGGAGATGCAGGTTC 351 
c/ebpα TATAGGCTGGGCTTCCCCTT AGCTTTCTGGTGTGACTCGG 94 
 
2.2.9 Protein Extraction and Quantification 
hASCs were seeded in 10cm tissue culture plates for protein assays. Upon reaching 
terminal time points, the cells were washed with PBS twice and collected using RIPA 
buffer (Abcam ab156034) containing phosphatase and protease inhibitors (Thermo 88666). 
The cells were lysed for 30 minutes at 4oC. The cell lysates were transferred into labelled 
tubes and centrifuged at 4oC (12,000RPM for 20minutes) to isolate the proteins and 
eliminate any cellular debris. Protein samples were quantified using BSA standard curves 
generated from Bradford assays (Bio-Rad 5000006). 
2.2.10 Coimmunoprecipitation assay (CoIP) 
CoIP was performed using the Pierce Crosslink Magnetic IP/Co-IP kit following 
manufacturer’s protocol (Thermo 88805).  Binding of antibodies to the proteins A/G 
magnetic beads was done by diluting the coupling buffer and lysis /wash buffer with 
ultrapure water. The tubes were placed on a magnetic stand to collect the beads for 1 
minute. After this step, the antibodies were diluted (1:10) with 20X coupling buffer and 
1:20 with IP lysis/wash buffer to get a final antibody concentration of 2-10µg per 100µl 
(Thermo Scientific). 100µl of prepared antibody solution was added to the beads, gently 
Table 2-2: Primers used for reverse transcriptase PCR 




mixed, and incubated on a rotator for 15mins vertexing gently every 5mins to ensure the 
beads remain in suspension. The beads were collected with a magnetic stand and the 
supernatant was discarded.  
Crosslinking of the bound antibody was done by diluting DSS 1:100 in DMSO 
(VWR; N182-5X10ML) to make 0.25mM DSS. 2.5µl of 20X coupling buffer, 4ul of 
0.25mM DSS and 43.5ul of ultrapure water to the beads to make up a total volume of 50ul. 
The DSS is added at 10X molar excess to the Pierce Protein Magnetic beads at 20uM 
working solution. The solution was incubated for 30miuntes and the beads were collected 
with a magnetic stand. The flow through was saved to verify antibody crosslinking. Elution 
buffer was added to the mix, vortexed, the supernatant removed, and this process was 
repeated three times and the antibody-crosslinked beads were stored at 4°C or proceeded 
to antigen precipitation.  
The cells were washed with PBS and ice-cold IP lysis/wash buffer (Table 2-3) to 
the cells and incubated on ice for 5minutes with periodic mixing. The lysate was micro-
centrifuged at ~13,000XG for 10minutes to pellet the cell debris and the supernatant was 
transferred to a new tube for protein concentration determination. 500ul of protein lysate 
or 200µg of protein sample was added to the tube containing crosslinked magnetic beads 
and incubated overnight at 4°C on a rotator. Then the beads were collected with a magnetic 
stand, the unbound sample was collected for western blot analysis. The collected beads 
were washed two times with IP lysis/wash buffer and one time with ultrapure water. Beads 
were collected on a magnetic stand and supernatants were discarded. 50µl of elution buffer 
was added to the collected beads and incubated for 5 min at room temperature on a rotator. 
Beads were collected magnetically and saved at -20°C for western blot analysis. 10µl of 




neutralization buffer was added to each 100µl of eluate to neutralize the low pH of the 
sample collected. This elution step is repeated one more time for optimal antigen recovery. 
 
 






2.2.11 Western blot 
SDS-PAGE was performed using a Mini PROTEAN TGXTM. Samples were loaded 
in a polyacrylamide gel (Bio-Rad 4561084) at equal concentration, following the 
manufacturer’s protocol. Proteins were transferred using transblot TurboTM PVDF transfer 
pack (Thermo scientific 88518). After transfer, the membranes were cut into equal sizes 
and blocked in 5% milk for 2 hours in 1X TBS with 0.1% Tween. The membrane was 
probed overnight with primary antibody (1:1000), washed 5 times and probed with 
secondary antibody (1:1000). The blots were developed and visualized with ECL and 
chemiluminescence (Bio-Rad 1705060). Below is a table showing the list of antibodies 




Table 2-3: Volume of IP Lysis/Wash Buffer to use for different standard culture plates  







Host specie Company Catalog no Dilution  
MED12 250kDa Rabbit Bethyl A300-774A 1:1000 
MED13 268kDa Rabbit Bethyl A301-278A 1:1000 
CDK8 58kDa Rabbit Bethyl A302-501A-
M 
1:1000 
CCNC 28kDa Rabbit Bethyl A301-989A 1:1000 
PPARγ 57.6kDa Rabbit Thermo Fisher PA3-821A  1:500 
Gapdh 37kDa Rabbit Abcam Ab9485 1:1000 
Goat Anti-Rabbit 
IgG H&L (HRP) 
  Rabbit 
(Target) 
Abcam Ab6721 1:500 
C/EBPα 37kDa Rabbit Thermo Fisher PA1-337 1:1000 
 
2.3 Statistical Analysis 
Statistical analysis was performed using the students 2-tailed T tests where 
necessary. 
2.4 Results 
2.4.1 MED12 siRNA effectively decreased MED12 transcript and protein 
expression 
To study MED12 in adipogenesis we first needed to ensure that the knockdown 
persisted over a differentiation time course of 14 days. To do this, the levels of MED12 
were diminished via siRNA-mediated transfections and validation of the efficacy of the 
knockdown was determined by qRT-PCR assays (Figure 2-1A), and Western blots (Figure 
2-1B). It was observed that there was a significant loss of MED12 transcript i.e., ~70% 
reduction (P-value <0.05) in the amount of MED12 transcript observed at 3-, 7- and 14-
days post transfection (Figure 2-1A) and approximately a 70% drop in MED12 protein as 
quantified via ImageJ analysis (Figure 2-1C). 
Table 2-4: Antibodies used in Western blot assay 



























Figure 2-1: Validation of MED12 knockdown. A. siRNA-mediated 
knockdown of MED12 was analyzed by qRT-PCR. Results indicate a 
significant decrease (p<0.05) of MED12 gene normalized to GAPDH. 
Studies were performed in biological triplicates and error bars denote SE of 
the mean and (**) indicates P<0.05 for all genes. B. Western blot was 
performed to validate successful reduction in MED12 protein after 
knockdown. C. ImageJ analysis was used to quantify amount of protein 
remaining after knockdown. Western blot analysis represents biological 
triplicates of whole cell lysates, normalized to GAPDH. 
 





2.4.2 Characterization of Adipose Stem Cells 
Once we had established reliable and robust knockdown of MED12 during 
adipogenesis, we wanted to determine the influence of the knockdown on adipogenesis We 
first observed differentiation through phase contrast imaging (Figure 2-2A) and then 
studied the morphological changes and formation of lipid vesicles through Oil Red-O 
staining and staining extraction technique (Figure 2-2B & Figure 2-2C). In this experiment, 
adipocyte differentiation was induced, and cells were fixed and imaged at 3-, 7- and 14-
days following siRNA mediated knockdown of MED12. A single transfection was 
performed 24 hours prior to initiating differentiation. Imaging was done using a Biotek 
citation imager and adipogenic differentiation was indicated via Oil Red O stain, in which 
the lipid droplets were stained red and indicated with arrows. Results of this study show an 
increase in the number of lipid droplets over time in the negative control cells with a 
striking decrease in adipocyte differentiation and lipid droplet accumulation following the 
knockdown of MED12. From this study, we can conclude that MED12 may play a role in 
















   
Figure 2-2: Characterization of adipose stem cells. A. Phase contrast of 
adipogenic differentiated hASCs at 3,7- and 14-days post transfection. B. Color 
micrograph of adipogenic differentiated hASCs at 3,7- and 14-days post 
transfection. Staining of lipid droplets was done using Oil Red O and lipid 
droplets are indicated with arrows. C. Oil Red O extraction. All data points are 
the average of three biological replicates and error bars indicate standard error of 
the mean and (**) indicates P<0.05 for all genes.  
 








2.4.3 MED12 knockdown plays a role in the expression of adipogenic transcription 
factors 
To further confirm and investigate the influence of MED12 on adipogenesis, we 
examined adipogenic markers PPARγ and C/EBPα, both well characterized transcription 
factors responsible for inducing early adipogenesis. We performed qRT-PCR to examine 
expression levels PPARγ, (Figure 2-3A) and C/EBPα (Figure 2-3B) and observed a 
decrease in expression following the knockdown of MED12. This supports the hypothesis 
that MED12 does have a role in directing adipogenic-specific gene expression and may be 
involved in activating the genes that are responsible for adipocyte differentiation of adipose 
stem cells. 
Since a decrease in transcript levels does not always translate to a decrease in 
protein expression, we further confirmed the influence of the MED12 knockdown on 
adipogenic transcription factors by examining the protein levels of PPARγ, a master 
regulator of adipogenesis. This study was carried out by running a western blot assay of 
PPARγ at day 3, 7 and 14 (Figure 2-3C), following the induction of adipogenesis. We 
found that the knockdown of MED12 significantly reduced the protein expression of 
PPARγ at all time points after induction of adipogenesis in hASCs via ImageJ analysis 
(Figure 2-3D). This result suggests that MED12 acts to inhibit differentiation, suggesting 













Figure 2.3: MED12 knockdown plays a role in the expression of adipogenic 
transcription factors. A. qRT-PCR confirmed decrease in adipogenesis after 
3 and 7 days and an increase after 14days of induction with significant 
increases in transcript for PPARγ. P values 0.048772, 0.051821, 0.077405 for 
days 3, 7 and 14 days, respectively.  








B. qRT-PCR confirmed decrease in CEBPα. p values 0.008403,0.011366 
and 0.000141 for days 3, 7 and 14 days, respectively. CEBPα and PPARγ 
genes are normalized to gapdh and studies were performed in triplicates. 
Error bars are the average of three biological replicates and represent 
standard error of the mean and (**) indicates P<0.05 for all genes.  















C. Protein analysis confirms a decrease in PPARγ expressions following 
induction of adipogenesis at day 3, 7 and 14 days. D. ImageJ analysis was 
used to quantify precent protein remaining after knockdown. Western blot 













2.4.4 MED12 influences other subunits of the kinase module during adipogenesis 
Previous studies have linked the kinase domain, specifically MED12 and MED13, 
to the regulation of gene expression during development. It has also been observed that 
MED12 is essential for CDK8 and CCNC enzymatic activity. MED12 interacts with CDK8 
through a physical association with Cyclin C (CCNC), thus making it vital to the function 
of the kinase domain57. Given these relationships, we were interested in knowing how the 
knockdown of MED12 influenced the expression of other subunits of the kinase module 
such as MED13 (Figure 2-4A), CDK8 (Figure 2-4B) and CCNC (Figure 2-4C). qRT-PCR 
was used to determine the transcript levels of the kinase module subunits while western 
blots were used to determine the protein expression of each subunit following the 
knockdown of MED12 and results were analyzed via ImageJ analysis (Figure 24D&E).  
We observed an increase in MED13 at day 7 and 14, CDK8 at day 14 and CCNC at day 7. 
Western blots result indicates that CDK8 was not affected in any way by the knockdown 
of MED12 and CCNC had low expressions in the absence of MED12. This fluctuation in 
patterns of expression may be the result of compensation for a downstream transcriptional 
block of the cells following the reduced expression of MED12. Although the mechanism 
via which MED12 performs this function is unknown, MED12 dependent CDK activation 
is essential for nuclear transduction of the signals which are propagated by the different 
signaling pathways in which MED12 is genetically and biochemically linked.  
After several attempts to run a western blot assay on MED13, we have not been 
able to get the bands to show up despite trying different methods and different gels. We 
hope to get some results, but at the time of writing this result, we are yet to get any results 
for MED13. 








Figure 2.4: MED12 influences other subunits of the kinase module 
during adipogenesis. A. qRT-PCR showing a significant decrease of 
transcript levels of MED13 at day-3, a significant increase at 7 days 
and little change at day 14.  








B. qRT-PCR showing a significant decrease in transcript levels of 
CDK8 at day-3 and 7 and a return closer to controls by day 14.  









C. qRT-PCR showing a decrease in transcript levels of CCNC at day-3 and a 
significant increase at day 7 and a further decrease at day 14. Results are 
normalized to gapdh and were performed in biological triplicates. Error bars are 
the average of three biological replicates and represent standard error of the 















Figure 2-4: MED12 influences other subunits of the kinase module during 
adipogenesis. D. Protein analysis confirms a decrease in expressions of CCNC and 
no change in the expression of CDK8 following knockdown of MED12 and induction 
of adipogenesis at day 3, 7 and 14 days. E. ImageJ analysis was used to quantify 
precent protein remaining after knockdown. Western blot analysis represents 
biological triplicates of whole cell lysates, normalized to GAPDH. 
 




2.4.5 Interaction of subunits within the kinase module 
We wanted to know the role of MED12 in maintaining the structural integrity of 
the complex by monitoring the physical interactions of protein complexes within the cells. 
To accomplish this goal, we used Co-Immunoprecipitation assays and antibodies targeting 
MED12 to pull down MED12 and identify which part of the kinase module are directly 
interacting with this specific subunit. Each Co-IP experiment was subjected to SDS-PAGE 
and membrane transfer before being probed for MED12 as well as other subunits of the 
kinase module and adipogenic transcription factors like PPARγ and C/EBPα.  
Results from this study indicate that CDK8, CCNC, C/EBPα and PPARγ were each 
pulled down along with MED12 at all the timepoints as observed in the elute. However, 
CDK8 was expressed in both elute and unbound cells which could indicate that there might 
be more CDK proteins not interacting with MED12 or the amount of antibody used for the 
target protein is saturated hence the appearance of unbound proteins. It is also noteworthy 
to add that the results from Day 3 had a lot of background which hindered the bands from 
being seen clearly A repeat of the study may be carried out, but at the time of writing this 
























Figure 2-5: Coimmunoprecipitation assays of the proteins of the kinase subunits and 
transcription factors at Day 0,3,7 and 14 following the loss of MED12. Co-IP for 
MED12 was being done to confirm knockdown and possibly account for any 






CHAPTER 3  
3.1 CONCLUSION 
3.1.1 Understanding the mechanism of Regulation 
This study sought to investigate the role of MED12 in relation to the Mediator 
complex and kinase domain to better understand transcriptional control of adipogenesis in 
hASCs. The goal was to not only determine changes in adipogenesis in the absence of 
MED12, but to also identify and understand interactions between MED12 and transcription 
factors that control adipogenesis. The results of this study have helped to disclose some 
insights into how cell-type specific gene expression is regulated by MED12. The 
knockdown of MED12 indicated a decrease in adipocyte differentiation and lipid droplet 
formation as compared to the control which had an increased number of lipid droplets 
(Figure 2-2). We then went further to investigate the relationship between MED12 and 
adipogenic transcription factors such as PPARγ and C/EBPα, master regulators of 
adipogenesis. We performed qRT-PCR and western blot assays which indicated reduced 
transcript and protein of adipogenic transcription factors following the diminished 
expression of MED12 (Figure 2-3). This indicates a regulatory role for MED12 in directing 
adipogenesis and provides an additional layer of understanding for how MED12 controls 
cell-type specific gene expression profiles.  
Once we had established a role for MED12 in adipogenesis, we were interested in 
knowing how the knockdown of MED12 influenced other subunits of the kinase domain. 
Here, the knockdown of MED12 showed a decrease in MED13 transcript at day 3 and an 
increase at days 7 and 14. The increase in transcript level may indicate MED13 trying to 
compensate for the decrease in MED12 expression. Knockdown of MED12 led to a 




decrease in CDK8 transcript at day 3 and day 7, a decrease in Cyclin C on day 3 and 
subsequent increase of Cyclin C transcript at days 7 and 14 (Figure 2-4). These results may 
indicate that MED12 is essential for activating the CDK/Cyclin C kinase activity and 
subsequent transcriptional activation of target genes. In addition, for the protein levels of 
the kinase module, CDK8 showed no significant decrease in the levels of protein at all 
experimental time points and suggests that MED12 does not have any effect on the CDK8 
kinase module, and so CDK8 may act independently of the Mediator complex as reported 
by previous literature44. Finally, we aimed to determine the role of MED12 as it functions 
in the Mediator complex and its role in maintaining the structural integrity of the kinase 
module. Co-immunoprecipitation assays were performed to determine interactions 
between MED12, CDK8, Cyclin C, C/EBPα and PPARγ (Figure 2-5). Results indicate that 
CDK8 was present in the elute and bound to MED12 while CCNC is not bound to MED12. 
These results suggests that an amount of CDK8 remains free of MED12 or that the amount 
of CDK8 antibody used for co-IP is saturated and our assay requires further optimization. 
CEBPα was found bound to MED12 suggesting a possible interaction between MED12 
and CEBPα. Given the importance of C/EBPα, and PPARγ during adipogenesis, and based 
on our result, we suggest that MED12 interacts with the transcription factors and kinase 
module to direct gene expression.  
Taken together, this study provides evidence for a regulatory role of MED12 in 
directing adipogenesis of hASCs. These findings aid in our understanding of adipocyte 
biology and the potential role for these cells in regenerative medicine and therapeutics for 
clinical research. Adipogenesis has become one of the most extensively studied processes, 




and the focus on the availability of human adipose stem cell models to study 
adipogenesis57.  
Previous studies have linked the kinase domain, specifically MED12 and MED13 
to the regulation of gene expression during development. Both MED12 and MED13 play 
a vital role in eye and wing development in Drosophilia where the loss of MED12 was 
shown to result in physiological differences of wing structure. In zebrafish, MED12 has 
been linked as a co-factor in neural crest and endoderm development1. MED12 has been 
identified as being critical for CDK8 and CCNC enzymatic activity and interacts with 
CDK8 through a physical association with Cyclin C (CCNC), thus making it a vital part of 
the function of the kinase domain44.  
Here, we show a novel study that demonstrates that the knockdown of MED12 in 
hASCs blocks differentiation and reduces adipogenesis indicating a cell specific role for 
this protein in adipogenesis.  In this study, we demonstrated that the knockdown of MED12 
resulted in decreased adipogenesis and transcription of adipocyte transcription factors, 
suggesting that MED12 is required for maintaining PPARγ and C/EBPα gene expression. 
As PPARγ and C/EBPα are required for adipogenesis55, the data presented in this thesis 
provides additional information to the field by identifying another factor critically involved 
in the initiation of differentiation. Hence knowledge from the study can be used in 
understanding and treating human disease such as obesity by stopping transcriptional mis-
regulation and understanding regulatory mechanisms that can lead to several metabolic 
conditions, including heart diseases, stroke, diabetes etc. 




3.1.2 Future work 
The insight gained from the research presented here has led to several questions and 
opportunities for future investigation. From our studies, many questions arise about how 
exactly MED12 regulated adipogenesis. This can be answered using chromatin 
immunoprecipitation (ChIP) assays which uncovers DNA-proteins interaction within the 
cell. It may be vital to determine subunit interactions and genome occupancy within the 
cells and studies on chromatin modifiers of the kinase subunit genes to better understand 
binding patterns of MED12 and the Mediator complex with the general transcriptional 
machinery. In addition, a further understanding of how other subunits of the kinase module 
influence adipogenesis is of great interest. To achieve this goal, shRNA-containing 
lentivirus will be used to knockdown specific subunits of the Mediator complex kinase 
module. This type of knockdown technology allows for the integration of shRNA into the 
genome and the establishment of cell lines, ultimately leading to greater consistency and 
overall efficiency in studies. Finally, questions related to global gene expression changes 
during adipogenesis following the knockdown of proteins like Med12 remain. Microarrays 
and RNAseq will help to effectively establish what genes are affected by the knockdown 
induced decreased expression of MED12 and aid in identifying novel targets of MED12 
that may be used to control cell fate. Going forward with this study will aid in further 
understanding the processes of adipogenesis and the relationship between the Mediator 
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